Skip to main content
OpenTrials
Completed

NCT Number: NCT00998790

A Post-Market Study of the AMS AdVance™ Male Sling System for the Treatment of Male Stress Urinary Incontinence

A prospective, multi-center study of the AdVance Male Sling for Stress Urinary Incontinence. The purpose of this study is to obtain surgical technique data for use in physician education and training and to collect early clinical outcomes data for future publication. This study is not designed to statistically demonstrate safety and efficacy of the device.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Stress Urinary Incontinence Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Lower Urinary Tract Symptoms Male Urogenital Diseases Neoplasm Metastasis Neoplasms Neoplastic Processes Pathologic Processes Pathological Conditions, Signs and Symptoms Signs and Symptoms Urinary Incontinence Urinary Incontinence, Stress Urination Disorders Urogenital Diseases Urologic Diseases Urological Manifestations

Age range

40 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Universitaire Ziekenhuisen Leuven, Leuven, Belgium

Loading trial locations.

About this study

A prospective, multi-center study conducted under a common implant and follow-up protocol. The study will collect pre-operative urologic testing, medical history and subject quality of life (Incontinence Quality of Life Questionaire). Intra-operative procedural data will be collected.

Pad weight and incontinence severity rating (using the ICIQ survey) will be used to characterize continence status.

Post-operative complications, urologic testing, and subject quality of life will be collected at six weeks and three, six, 12, and 24 months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The subject has agreed to be implanted with the AMS AdVance Male Sling System.
  • The subject is willing and able to give valid informed consent.
  • The subject is ≥40 years of age.
  • The subject has confirmed stress urinary incontinence for at least 6 months and uses no more than 8 pads per day for incontinence management and has less than 250 grams on the 24-hour pad weight test.
  • The subject has any of the following: an observable degree of incontinence during stress related activities, more than one pad is used in a 24 hour period, has more than two episodes of incontinence per day.
  • Internal sphincter contractility confirmed by endoscopic view.
  • The subject's primary etiology is TUR, TURP, or radical prostatectomy.
  • Pre-existing urological conditions, other than incontinence have been treated and are under control.
  • The subject is willing and able to return for follow-up evaluations and questionnaire completion according to the study protocol.
  • The subject is a good surgical candidate.

Exclusion criteria

  • The subject has a neurogenic bladder condition that is not treatable or controllable by pharmacological or alternative methods.
  • The subject has a post-void residual ≥ 100 cc.
  • The subject has detrusor-external sphincter dyssynergia.
  • The subject has a urinary tract infection (UTI).
  • The subject was treated with pelvic radiation within the last 6 months.
  • The subject currently has an inflatable penile prosthesis.
  • The subject self-catheterizes.
  • The subject has symptomatic or unstable bladder neck structure disease.
  • The subject has a history of urethral strictures that may require repetitive instrumentation.
  • The subject has previously had a urethral Sling System, an AMS Sphincter 800™, or any implanted device for the treatment of urinary incontinence (not including bulking agents).
  • The subject has a history of connective tissue or autoimmune conditions.
  • The subject has a compromised immune system.
  • The subject has renal insufficiency, and upper and/or lower urinary tract relative obstruction.
  • The subject's reading level is judged inadequate for reading and understanding the quality of life questionnaires and other study materials.

Treatment and study plan

American Medical Systems (AMS) AdVance™ Male Sling System

Device

The AMS AdVance™ Male Sling System was developed to treat urinary stress incontinence in men resulting from intrinsic sphincter deficiency (ISD). The AdVance™ Male Sling System procedure is minimally invasive and consists of using two single-use needle passers and passing them through two small incisions over the obturator foramen. The needles are pushed in an arc through the tissue and exited at a perineal incision. Once the passers are through the perineal incision, the Sling System mesh arms are attached to the needles which are then pulled back through the needle track to their points of origin over the obturator foramen. The Sling System is subsequently tensioned and all incisions are closed.

Other names: Device: AdVance Male Sling

Primary outcomes

  1. Change in 1-hour Pad Weight Test From Baseline to 24 Month Follow-up

    Time frame: 24 months

    1 hour pad weight tests were conducted at baseline at all successive follow-up visits. Baseline scores were compared to last visit follow-up at 24 months.

  2. Change in 24-hour Pad Weight Test From Baseline to 24 Month Follow-up

    Time frame: 24 months

    24 hour pad weight tests were conducted at baseline at all successive follow-up visits. Baseline scores were compared to last visit follow-up at 24 months.

  3. Percentage of Subjects in Each Range of Pads Per Day Use

    Time frame: Baseline

    Evaluate the proportion of subjects using the following categories of pads per day from baseline to the final 24 month visit follow up 0 to 1 pads per day; 2 -3 pads per day; 4-5 pads per day; 6-7 pads per day; 8-9 pads per day; 10 or greater pads per day

  4. Percentage of Subjects in Each Range of Pads Per Day Use

    Time frame: 24 months

    Evaluate the proportion of subjects using the following categories of pads per day from baseline to the final 24 month visit follow up 0 to 1 pads per day; 2 -3 pads per day; 4-5 pads per day; 6-7 pads per day; 8-9 pads per day; 10 or greater pads per day

Secondary outcomes

  1. To Evaluate Patient Quality of Life

    Time frame: 24 months

    The Incontinence Quality of Life Questionnaire (I-QOL) is a 22 questionnaire that evaluates a subject's quality of life with respect to urinary problems/incontinence. A lower score correlates with more severe incontinence, and an increase from baseline indicates an improvement in quality of life. The score scale is 0 - 100.

    The International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) is a 4 question tool that quantifies the impact on quality of life from incontinence. A decrease from baseline to follow-up indicates an improvement in quality of life. The score scale is 0-21.

Sponsors and collaborators

Lead sponsor

Boston Scientific Corporation

Industry

Registry information

Important dates

Study start
2007
Primary completion
2012
Study completion
2012
First posted
Oct 20, 2009
Registry last updated
Oct 22, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.